Clinical versus fixed warfarin dosing and the impact on quality of anticoagulation (The ClinFix trial)
<p dir="ltr">Different dosing strategies exist to initiate warfarin, most commonly fixed warfarin dosing (FWD), clinical warfarin dosing (CWD), and genetic‐guided warfarin dosing (GWD). Landmark trials have shown GWD to be superior when compared to FWD in the EU‐PACT trial or CWD in...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , , , , , , , , , , |
| Published: |
2024
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513545604956160 |
|---|---|
| author | Amr M. Fahmi (21632909) |
| author2 | Ahmed El Bardissy (21632912) Mohamed Omar Saad (12535545) Mohamed Nabil Elshafei (9960500) Loulia Bader (14151585) Ahmed Mahfouz (737928) Mohamed Kasem (8602740) Osama Abdelsamad (14151600) Abdelnasser Elzouki (21632915) Christina L. Aquilante (8106603) Fatima Mraiche (715733) Ezeldin Soaly (14151603) Ihab El Madhoun (21632918) Nidal Asaad (284935) Abdulrahman Arabi (8100536) Eman Alhmoud (13955766) Hazem Elewa (3592601) |
| author2_role | author author author author author author author author author author author author author author author author |
| author_facet | Amr M. Fahmi (21632909) Ahmed El Bardissy (21632912) Mohamed Omar Saad (12535545) Mohamed Nabil Elshafei (9960500) Loulia Bader (14151585) Ahmed Mahfouz (737928) Mohamed Kasem (8602740) Osama Abdelsamad (14151600) Abdelnasser Elzouki (21632915) Christina L. Aquilante (8106603) Fatima Mraiche (715733) Ezeldin Soaly (14151603) Ihab El Madhoun (21632918) Nidal Asaad (284935) Abdulrahman Arabi (8100536) Eman Alhmoud (13955766) Hazem Elewa (3592601) |
| author_role | author |
| dc.creator.none.fl_str_mv | Amr M. Fahmi (21632909) Ahmed El Bardissy (21632912) Mohamed Omar Saad (12535545) Mohamed Nabil Elshafei (9960500) Loulia Bader (14151585) Ahmed Mahfouz (737928) Mohamed Kasem (8602740) Osama Abdelsamad (14151600) Abdelnasser Elzouki (21632915) Christina L. Aquilante (8106603) Fatima Mraiche (715733) Ezeldin Soaly (14151603) Ihab El Madhoun (21632918) Nidal Asaad (284935) Abdulrahman Arabi (8100536) Eman Alhmoud (13955766) Hazem Elewa (3592601) |
| dc.date.none.fl_str_mv | 2024-06-10T09:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1111/cts.13797 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Clinical_versus_fixed_warfarin_dosing_and_the_impact_on_quality_of_anticoagulation_The_ClinFix_trial_/29445467 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences Warfarin dosing Clinical warfarin dosing (CWD) Fixed warfarin dosing (FWD) Genetic-guided warfarin dosing (GWD) Anticoagulation |
| dc.title.none.fl_str_mv | Clinical versus fixed warfarin dosing and the impact on quality of anticoagulation (The ClinFix trial) |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">Different dosing strategies exist to initiate warfarin, most commonly fixed warfarin dosing (FWD), clinical warfarin dosing (CWD), and genetic‐guided warfarin dosing (GWD). Landmark trials have shown GWD to be superior when compared to FWD in the EU‐PACT trial or CWD in the GIFT trial. COAG trial did not show differences between GWD and CWD. We aim to compare the anticoagulation quality outcomes of CWD and FWD. This is a prospective cohort study with a retrospective comparator. Recruited subjects in the CWD (prospective) arm were initiated on warfarin according to the clinical dosing component of the algorithm published in www.warfarindosing.org. The primary efficacy outcome was the percentage time in the therapeutic range (PTTR) from day 3 to 6 till day 28 to 35. The study enrolled 122 and 123 patients in the CWD and FWD, respectively. The PTTR did not differ statistically between CWD and FWD (62.2 ± 26.2% vs. 58 ± 25.4%, <i>p</i> = 0.2). There was also no difference between both arms in the percentage of visits with extreme subtherapeutic international normalized ratio (INR) (<1.5; 15 ± 18.3% vs. 16.8 ± 19.1%, <i>p</i> = 0.44) or extreme supratherapeutic INR (>4; 7.7 ± 14.7% vs. 7.5 ± 12.4%, <i>p</i> = 0.92). We conclude that CWD did not improve the anticoagulation quality parameters compared to the FWD method.</p><h2>Other Information</h2><p dir="ltr">Published in: Clinical and Translational Science<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1111/cts.13797" target="_blank">https://dx.doi.org/10.1111/cts.13797</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_8d6fb556b1be8d610c729c4a7529373a |
| identifier_str_mv | 10.1111/cts.13797 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/29445467 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Clinical versus fixed warfarin dosing and the impact on quality of anticoagulation (The ClinFix trial)Amr M. Fahmi (21632909)Ahmed El Bardissy (21632912)Mohamed Omar Saad (12535545)Mohamed Nabil Elshafei (9960500)Loulia Bader (14151585)Ahmed Mahfouz (737928)Mohamed Kasem (8602740)Osama Abdelsamad (14151600)Abdelnasser Elzouki (21632915)Christina L. Aquilante (8106603)Fatima Mraiche (715733)Ezeldin Soaly (14151603)Ihab El Madhoun (21632918)Nidal Asaad (284935)Abdulrahman Arabi (8100536)Eman Alhmoud (13955766)Hazem Elewa (3592601)Biomedical and clinical sciencesCardiovascular medicine and haematologyPharmacology and pharmaceutical sciencesWarfarin dosingClinical warfarin dosing (CWD)Fixed warfarin dosing (FWD)Genetic-guided warfarin dosing (GWD)Anticoagulation<p dir="ltr">Different dosing strategies exist to initiate warfarin, most commonly fixed warfarin dosing (FWD), clinical warfarin dosing (CWD), and genetic‐guided warfarin dosing (GWD). Landmark trials have shown GWD to be superior when compared to FWD in the EU‐PACT trial or CWD in the GIFT trial. COAG trial did not show differences between GWD and CWD. We aim to compare the anticoagulation quality outcomes of CWD and FWD. This is a prospective cohort study with a retrospective comparator. Recruited subjects in the CWD (prospective) arm were initiated on warfarin according to the clinical dosing component of the algorithm published in www.warfarindosing.org. The primary efficacy outcome was the percentage time in the therapeutic range (PTTR) from day 3 to 6 till day 28 to 35. The study enrolled 122 and 123 patients in the CWD and FWD, respectively. The PTTR did not differ statistically between CWD and FWD (62.2 ± 26.2% vs. 58 ± 25.4%, <i>p</i> = 0.2). There was also no difference between both arms in the percentage of visits with extreme subtherapeutic international normalized ratio (INR) (<1.5; 15 ± 18.3% vs. 16.8 ± 19.1%, <i>p</i> = 0.44) or extreme supratherapeutic INR (>4; 7.7 ± 14.7% vs. 7.5 ± 12.4%, <i>p</i> = 0.92). We conclude that CWD did not improve the anticoagulation quality parameters compared to the FWD method.</p><h2>Other Information</h2><p dir="ltr">Published in: Clinical and Translational Science<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1111/cts.13797" target="_blank">https://dx.doi.org/10.1111/cts.13797</a></p>2024-06-10T09:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1111/cts.13797https://figshare.com/articles/journal_contribution/Clinical_versus_fixed_warfarin_dosing_and_the_impact_on_quality_of_anticoagulation_The_ClinFix_trial_/29445467CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/294454672024-06-10T09:00:00Z |
| spellingShingle | Clinical versus fixed warfarin dosing and the impact on quality of anticoagulation (The ClinFix trial) Amr M. Fahmi (21632909) Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences Warfarin dosing Clinical warfarin dosing (CWD) Fixed warfarin dosing (FWD) Genetic-guided warfarin dosing (GWD) Anticoagulation |
| status_str | publishedVersion |
| title | Clinical versus fixed warfarin dosing and the impact on quality of anticoagulation (The ClinFix trial) |
| title_full | Clinical versus fixed warfarin dosing and the impact on quality of anticoagulation (The ClinFix trial) |
| title_fullStr | Clinical versus fixed warfarin dosing and the impact on quality of anticoagulation (The ClinFix trial) |
| title_full_unstemmed | Clinical versus fixed warfarin dosing and the impact on quality of anticoagulation (The ClinFix trial) |
| title_short | Clinical versus fixed warfarin dosing and the impact on quality of anticoagulation (The ClinFix trial) |
| title_sort | Clinical versus fixed warfarin dosing and the impact on quality of anticoagulation (The ClinFix trial) |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences Warfarin dosing Clinical warfarin dosing (CWD) Fixed warfarin dosing (FWD) Genetic-guided warfarin dosing (GWD) Anticoagulation |